sacituzumab tirumotecan

Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate targeting trophoblast cell surface antigen 2, which has been shown to significantly extend the survival of patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy. Methods In this phase III clinical … Read more